

## ASX Announcement

### Race Board Changes

- Dr Peter Smith joins Race Board as Independent Non-Executive Director, bringing decades of experience in healthcare and capital markets.
- Appointment adds a further broad, international network of pharmaceutical and investor contacts.
- Daniel Sharp resigned from Independent Non-Executive Director role.

---

**29 June 2023** – Race Oncology Limited (“Race”) is pleased to announce the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests.

**Chair, Mary Harney commented:** *“I sincerely thank Danny for his dedication and service to Race since his appointment and wish him every success in his future endeavours.*

*It is pleasing to welcome Dr Pete Smith who brings an exceptional blend of healthcare and capital markets expertise to our Board. With his deep understanding of both small and big pharma, and commercial skillset, we expect Pete will make invaluable contributions as we drive bisantrene’s scientific and commercial outcomes.”*

Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies.

He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.)

Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A.

His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.

Subject to shareholder approval, Dr Smith will be issued 182,792 options to acquire shares in the Capital of the Company at an exercise price of \$2.03 each and expiring 5 years from the date of issue. One third of the options will vest 12 months from the date of issue and the remaining two thirds of the options will vest monthly over the following 24 months, provided that Dr Smith remains as a Director of the Company during the vesting period.

--ENDS--

### **About Race Oncology (ASX: RAC)**

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called bisantrene.

Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that bisantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for bisantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of bisantrene. Learn more at [www.raceoncology.com](http://www.raceoncology.com)

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

#### **Release authorised by:**

Damian Clarke-Bruce, CEO/MD on behalf  
of the Race Board of Directors  
[damian.clarke-bruce@raceoncology.com](mailto:damian.clarke-bruce@raceoncology.com)

#### **Media contact:**

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)